



Cumulative Index 2002

Volume 29

March	RECENT ADVANCES IN NEONATAL GASTROENTEROLOGY, pages 1–201
June	NEONATAL NUTRITION, pages 203–356
September	PAIN IN VULNERABLE INFANTS, pages 357–583
December	PERINATAL BRAIN INJURY, pages 585–882

Note: Page numbers of article titles are in **bold face** type.

A

Abdominal wall, gastroschisis of, surgical treatment of, 11–12

Acetaminophen

maternal, neonatal effects of, 514
metabolism of, polymorphisms in, 524–525
pharmacokinetics of, 520–521

Acetoacetate, as cerebral metabolism fuel, 654–655

Acidosis, bilirubin neurotoxicity in, 766, 770

Activity, in pain assessment, 482

Acylovir, for herpes simplex virus infections, 807–809

Adrenergic nerve stimulation, intestinal circulation response to, 31

Adrenocorticotropin, as pain marker, 420–421

Aganglionosis (Hirschsprung's disease)
pathophysiology of, 98
surgical treatment of, 10–11

Aggressive nutrition, for preterm infants
description of, 227
enteral, 237–241
parenteral, 230–237

Agitation, versus pain, 479

Airway obstruction, ex utero intrapartum therapy for, 4

Alagille syndrome, cholestasis in, 168–169

Albumin, in bilirubin binding, 765, 767, 770

Aldosterone, as pain marker, 421

Alfentanil

adverse effects of, 502
for premedication, for endotracheal intubation, 543, 549
pharmacodynamics of, 498
pharmacokinetics of, 496

Allopurinol, for hypoxic-ischemic brain injury, 682–683

Amino acids

in parenteral nutrition, for very low birthweight infants, 231–233
metabolic defects of, hypoglycemia in, 253
placental transfer of, 208–213
requirements for, in infections, 297–299

Amphotericin B, for fungal infections, 813–814

Ampicillin, for bacterial meningitis, 797

Anaerobic bacteria, in meningitis, 802

Analgesia. *See also* Opioids: *specific agents*.
changing attitudes toward, 557–558
effects of, **511–534**

developmental considerations in, 522
in utero, 512–516
long-term, 525–526
maternal, 513–514
metabolism and, 514–516
opioids, 516–517
pharmacokinetics and, 517–522
polymorphisms and, 522–525

- receptor variability and, 525-526
tolerance, 518
- Anemia of prematurity, **283-294**
causes of, 284
erythropoietin in
deficiency of, 283-284
replacement of, 287-289
evaluation of, 285-286
in nutritional assessment, 323
iron in
metabolism of, 285
requirements for, 284-285
supplementation of, 288-289
long-term studies of, 289-290
transfusions for, 286-287
- Anesthesia
changing attitudes toward, 557-558
failure to use, 559-562
for fetus, 366-367
in stress response suppression, 417-419
standards of care for, 567
- Angiotensin II, constrictor activity of, in
necrotizing enterocolitis, 34
- Anomalies, gastrointestinal. *See* Gastroenterology, anomalies.
- Anorectoplasty, posterior sagittal, for
imperforate anus, 14
- Anoxia, brain injury in. *See* Hypoxic-ischemic
brain injury.
- Antacids, for gastroesophageal reflux, 152
- Anthropometric measurements, for nutritional
assessment, in preterm infants, 318
- Antibiotics, for chorioamnionitis, 615
- Antibodies, in breast milk, 42-43
- Anticoagulant therapy, for stroke, 715
- Anticonvulsants, for hypoxic-ischemic brain
injury, 679-680
- Antiphospholipid antibody syndrome,
maternal, fetal and newborn stroke in, 695
- α_1 -Antitrypsin deficiency, cholestasis in, 173
- Anus, imperforate, surgical treatment of, 13-14
- Apnea
in gastroesophageal reflux, 140, 145
in very low birthweight infants, brain
injury in, 781
- Apoptosis, in hypoxic-ischemic brain injury,
594-595
- Arachidonic acid
in nutrition
adverse effects of, 274-275
cognitive-behavioral development
and, 270-273
deficiency of, 267
formation of, 267
in breast milk, 266
in formulas, 266, 269, 276
structure of, 264
visual function and, 269-270
mediators of, 592-593
- Arginine, in nutrition, 56, 73
- Arterial pressure, reduction of, intestinal
circulation response to, 30
- asc amino acid transporters, 208-209
- Aspartate, in hypoglycemia, 657
- Asphyxia
brain injury in. *See* Hypoxic-ischemic
brain injury.
diving reflex in, 32-33
- ATA1 amino acid transporter, 209
- ATB amino acid transporters, 208
- Atracurium, for premedication, for
endotracheal intubation, 539-540, 544
- Atresia, esophageal, surgical treatment of, 8-9
- Atropine, for premedication, for endotracheal
intubation, 539-542, 544-547, 549
- Autoimmune diseases, maternal, fetal and
newborn stroke in, 695
- Autonomic nervous system, in heart rate
control, 430-431
- Autoregulation, pressure-flow, in intestinal
circulation, 30
- Autoregulatory escape, in intestinal circulation
response, 31
-
- B**
- Bacterial overgrowth, in short-bowel
syndrome, 187-188
- Bacteroides fragilis*, in meningitis, 802
- Barbiturates, for hypoxic-ischemic brain injury,
681-682
- Barker thrifty phenotype hypothesis, 203-205,
328-329
- Basal ganglia injury, in very low birthweight
infants, 778-779
- Beckwith-Wiedemann syndrome, hypoglyce-
mia in, 248

- Behavioral outcome
 in very low birthweight infants. *See*
 Very low birthweight infants, brain
 injury in.
 of pain, in ex-preterm children, 357-359,
 378-379
 of stroke, 715
- Behavioral state, in pain assessment, 471-473
- Benzathine penicillin G, for syphilis, 800-801
- Beta cells, partial excision of, for
 hyperinsulinemia, 15
- Beta-hydroxybutyrate, as cerebral metabolism
 fuel, 654-655
- Bethanechol
 for gastroesophageal reflux, 151
 pharmacology of, 119-120
- Bianchi procedure, for short-bowel
 syndrome, 189
- Bicarbonate, as pain marker, 676
- Bifidobacteria, as immunonutrients, 58
- Biliary tract
 atresia of, cholestasis in, 163, 165-166
 bile formation in, physiology of, 161-162
 cholestatic disease of. *See* Cholestasis.
 dysgenesis of, cholestasis in, 167-168
 paucity of ducts in, cholestasis in, 168
 secretions from, in host defense, 43-44
- Bilirubin
 excess of, in cholestasis. *See* Cholestasis.
 measurement of, in nutritional
 assessment, of preterm infants, 322
 neurotoxicity of, 763-776
 blood-brain barrier and, 765
 blood flow and, 766
 chemistry in, 764
 clinical implications of, 768-769
 drug effects on, 767
 factors increasing, 766-767
 hyperbilirubinemia interventions in,
 767-768
 immaturity issues in, 771-772
 in hemolysis, 771
 in very low birthweight infants,
 782-783
 mechanism of, 768
 metabolism and, 766
 treatment of, 769-771
- Biological markers, of pain, 415-425
 aldosterone, 421
 catecholamines, 419-420
 cortisol, 420-421
 endorphins, 421
 glucagon, 421
 growth hormone, 422
 in anesthesia, 417-418
 in surgery, 417-418
 insulin, 421
 prolactin, 422
 renin, 421
 stress response and, 416-419
- Biopsy, liver, in biliary atresia, 166
- Birth trauma, stroke in, 705
- Birthweight
 adult and childhood nutritional
 abnormalities related to, 203-205,
 213-214
 regaining of, in premature infants, 318
 very low. *See* Extremely low
 birthweight infants; Very low
 birthweight infants.
- Blood-brain barrier, bilirubin entry through,
 765-767, 770
- Blood flow, cerebral
 autoregulation of, in vulnerable neonates,
 380
 bilirubin entry and, 766
 periventricular leukomalacia and, 751
- Blood pressure
 breastfeeding effects on, 215
 in endotracheal intubation, premedication
 effects on, 538-542, 544-549
 in postoperative pain assessment, 474
 reduction of, intestinal circulation
 response to, 30
- Blood urea nitrogen, in nutritional assessment,
 of preterm infants, 323
- Body language, in pain assessment, 450,
 471-473, 475, 483
- Bombesin, trophic effects of, 78
- Bone metabolism, corticosteroids effects on,
 304-305
- Borreliosis, of central nervous system,
 805-806
- Bradycardia
 in very low birthweight infants, brain
 injury in, 781
 opioid-induced, 502
- Brain
 development of, pain effects on.
 See Neurodevelopmental effects,
 of pain.
 edema of, in hypoxic-ischemic brain
 injury, 679
 glucose transporters in, 655

- metabolism of, hypoglycemia and, 655-656
- Brain injury
hemorrhagic-ischemic, in preterm infants, 743-761
hypoglycemic, 649-672
hypoxic-ischemic. *See* Hypoxic-ischemic brain injury
in bilirubin toxicity, 763-776
in chorioamnionitis, 603-621, 753
in infections, 797-824
in periventricular-intraventricular hemorrhage, 743-750
in periventricular leukomalacia, 750-755
in stroke, 691-722
in very low birthweight infants, 777-795
- Branched-chain α -keto acid dehydrogenase deficiency, hypoglycemia in, 253
- Breast milk
bile salts in, 263
components of, in gastrointestinal host defense, 42-43
fatty acids in, 266
feedings with, for very low birthweight infants, 239-240, 783
for gastroesophageal reflux, 150
fortified, for preterm infants, 314-317
lipids in, 261
- Breastfeeding
adult nutritional disorders and, 215-216
of preterm infants, 338
- Bronchopulmonary dysplasia
corticosteroids for, 303
nutrition in, 339-340
- Bupivacaine
maternal, neonatal effects of, 514
pharmacokinetics of, 521-522
- Butyric acid, in nutrition, 58-59, 75-76
- Byler disease (progressive familial intrahepatic cholestasis), 171-172
-
- C**
- Calcium
accumulation of, in hypoxic-ischemic brain injury, 589
in formulas, for preterm infants, 337
levels of, in hypoglycemia, 657
- Calcium channel blockers
for hypoxic-ischemic brain injury, 681
for persistent hyperinsulinemic hypoglycemia of infancy, 250
- Calorimetry, indirect, for energy expenditure measurement, 299
- Candida*, in central nervous system infections, 813-814
- Candidemia, catheter-related, in short-bowel syndrome, 188
- Carbohydrate(s). *See also* Glucose.
malabsorption of, in short-bowel syndrome, 184
metabolic disorders of, hypoglycemia in, 251-253
supplements for, for preterm infants, 316-317
- Cardiopulmonary resuscitation, stroke in, 706
- Cardiovascular disease, in adults, early nutrition impact on, 203-204
- Cardiovascular effects, of opioids, 502
- Carnitine deficiency
hypoglycemia in, 253-254
in infections, 300
- Caroli's disease, cholestasis in, 167
- CAT amino acid transporters, 208
- Catabolism, in infections, nutritional aspects of, 296-302
- Catalase deficiency, in hypoxic-ischemic brain injury, 590
- Catecholamines, as pain marker, 419-420
- Catheters
central venous, for gastrointestinal disorders, 10
sepsis associated with, in short-bowel syndrome, 188
- Cefotaxime
for bacterial meningitis, 798
for Lyme disease, 806
- Ceftriaxone, for Lyme disease, 806
- Central nervous system. *See also* Brain.
enteric nervous system interactions with, 98
- Central venous catheters, for gastrointestinal disorders, 10
- Cerebral arteries, immature, periventricular leukomalacia and, 751
- Cerebral blood flow
autoregulation of, in vulnerable neonates, 380
bilirubin entry and, 766
hypoglycemia and, 655-656
periventricular leukomalacia and, 751
- Cerebral palsy
chorioamnionitis and

- clinical features of, 605-606
- genetic factors in, 613
- in encephalopathy, 608-612
- in premature infants, 606-608
- in term infants, 606
- prevention of, 614-615
- susceptibility to, 612-613
- due to maternal therapy. *See* Neurodevelopmental effects, of maternal therapies.
- postoperative pain assessment in, 480-485
- Cerebral venous thrombosis, stroke in, 707
- Checklist Pain Behavior, 484
- Chemokines
 - in hypoxic-ischemic brain injury, 592
 - intestinal, in host defense, 49-51
- Chickenpox, central nervous system involvement in, 812
- Child Facial Coding System, for pain assessment, 478
- Children's and Infants' Postoperative Pain Scale, 472, 476
- Children's Hospital of Eastern Ontario Pain Scale (CHEOPS), 471, 473, 475-476
- Cholangiography, in biliary atresia, 166
- Cholangitis, sclerosing, 167
- Cholecystokinin, trophic effects of, 77-78
- Cholestasis, neonatal, **159-180**
 - approach to, 162-163
 - causes of
 - bile flow impairment, 161-162
 - extrahepatic bile duct lesions, 163-167
 - genetic defects, 170-174
 - hepatobiliary transporter defects in, 171-172
 - hepatocyte disorders, 169-171
 - in parenteral nutrition, 174, 187
 - intrahepatic bile duct lesions, 167-169
 - metabolic liver diseases, 172-174
 - clinical features of, 160-161
 - evaluation of, 160-161
 - laboratory studies in, 160-161
 - physiologic, 162
 - susceptibility to, 162
 - treatment of, 174-175
- Cholesterol levels, breastfeeding effects on, 215
- Cholestyramine, for short-bowel syndrome, 186
- Cholylsarcosine, for short-bowel syndrome, 189
- Chorioamnionitis, **603-621**
 - antibiotics for, neurodevelopmental effects of, 726-731
 - brain injury in
 - cerebral palsy and. *See* Cerebral palsy, chorioamnionitis and.
 - clinical features of, 605-606
 - developmental delay in, 608
 - encephalopathy, 608-612
 - periventricular leukomalacia, 753
 - prevention of, 614-615
 - susceptibility to, 612-613
 - definition of, 604
 - incidence of, 604
 - microbiologic evidence of, 605
 - organisms causing, 603-604
- Chorioretinitis
 - in cytomegalovirus infections, 809-810
 - in toxoplasmosis, 815-817
- Chronic lung disease, in very low birthweight infants, brain injury in, 781
- Cimetidine, pharmacology of, 124-126
- Circulation, intestinal. *See* Intestinal circulation.
- Circumcision
 - anesthesia for, stress response in, 417
 - pain perception in, heart rate in, 433-434
- Cisapride
 - for gastroesophageal reflux, 151-152
 - pharmacology of, 120-122
- Citric acid cycle, glutamine in, 52
- Citrobacter diversus*, in meningitis, 799
- Clinical Scoring System, for pain assessment, 471, 473-474, 476
- Clostridium*, in meningitis, 802
- Coagulation disorders, maternal, fetal and newborn stroke in, 695-698
- Cocaine exposure, intrauterine, fetal and newborn stroke in, 698-699
- Cognitive-behavioral development, dietary fatty acids and, 270-273
- Cognitive dysfunction
 - chorioamnionitis related to, 606
 - in ex-preterm children, 357-359, 378-379
 - in stroke, 714-715
 - in very low birthweight infants.
See Very low birthweight infants, brain injury in.

- postoperative pain assessment in, 480-485
- Colon
Hirschsprung's disease of, 10-11, 98
malrotation of, surgical treatment of, 9
- Colostomy, for imperforate anus, 14
- Colostrum, for very low birthweight infants, 240
- COMFORT, for pain assessment, 462, 472, 474, 476
- Communication, of pain, 446-454, 553, 555-556
- Conceptual age, versus pain response, heart rate variability and, 434-436
- Congenital anomalies
cardiac, growth failure in, 340
gastrointestinal. *See*
Gastroenterology, anomalies.
- Consciousness, in fetus, 366-367
- Consolability, in pain assessment, 471-474
- Constipation, opioid-induced, 502-503
- Corticosteroids
gastrointestinal trophic effects of, 84
indications for, 302-303
maternal, neurodevelopmental effects of, 733-735
metabolic effects of, 302-307
energy expenditure, 306
implications of, for feeding, 307
in bronchopulmonary
dysplasia, 303
in growth and development, 303-305
lipids, 307
protein, 305-306
periventricular-intraventricular
hemorrhage and, 748
- Cortisol
as pain marker, 420-421
in fetus, 512
deficiency of, hypoglycemia in, 250-251
- Cortisone, for hypoglycemia, in infants of diabetic mothers, 248
- Coxsackievirus, in central nervous system infections, 809-810
- CRIS acronym, for pain assessment, 461-462, 471-472, 476, 480
- Crigler-Najjar syndrome, morphine metabolism in, 518
- Critical illness, pain assessment in, 479-480
- Crying, in pain assessment, 449, 471-473, 475, 482
- Cyclomydril, gastrointestinal effects of, 127-128
- Cyclooxygenase, in hypoxic-ischemic brain injury, 592-593
- Cystic adenomatoid malformation, fetal surgery for, 4
- Cystic fibrosis, cholestasis in, 173
- Cytokines
gastrointestinal trophic effects of, 84-85
in brain injury, associated with chorioamnionitis, 614
in hypoxic-ischemic brain injury, 591-592, 594
in periventricular leukomalacia, 753
intestinal, in host defense, 49-51
- Cytomegalovirus, in central nervous system infections, 809-810
-
- D**
- Dehydration, in hyperglycemia, 255
- Dendritic cells, intestinal, in host defense, 48
- Denial, of neonatal pain, management decisions and, 563-565
- Desensitization, in neonatal care workers, pain management decisions and, 563-565
- Dexamethasone
for bacterial meningitis, 799
gastrointestinal effects of, 84, 128
metabolic effects of, 303
energy expenditure, 306
in growth and development, 304
lipids, 307
protein, 305
- Diabetes mellitus
maternal
infants of, hypoglycemia in, 247-248
suboptimal intrauterine growth and, 204-205
type 2, breastfeeding protection against, 216
- Diaphragmatic hernia, prenatal versus postnatal, 3-4
- Diazoxide, for persistent hyperinsulinemic hypoglycemia of infancy, 250
- Diclofenac, maternal, neonatal effects of, 514
- Diet. *See* Nutrition.

- Diving reflex, necrotizing enterocolitis pathophysiology and, 32-33
- Docosahexaenoic acid, in nutrition
 - adverse effects of, 274-275
 - cognitive-behavioral development and, 270-273
 - deficiency of, 267
 - formation of, 267
 - in breast milk, 266-268
 - in formulas, 267, 269, 276
 - sources of, 273
 - structure of, 264
 - visual function and, 268-270

Doxapram, brain injury due to, 781

Drainage, peritoneal, for necrotizing enterocolitis, 12-13

Drugs, gastrointestinal effects of. *See* Pharmacology, of gastrointestinal tract.

E

EAAT amino acid transporters, 209

Échelle Douleur Inconfort Nouveau-Né, for pain assessment, 471-472, 476

Echogenic bowel, in fetus, 3

Echovirus, in central nervous system infections, 809-810

Ectoderm, enteric nervous system derived from, 99

Edema, cerebral, in hypoxic-ischemic brain injury, 679

Eicosapentaenoic acid, structure of, 264

Electroencephalography, in stroke, 708-709

Embryology, of enteric nervous system, 99-102

Encephalitis

- herpes simplex virus, 806-809
- stroke in, 705

Encephalopathy

- HIV, 811
- hypoxic. *See* Hypoxic-ischemic brain injury.
- in chorioamnionitis, 608-612

Endoderm, enteric nervous system derived from, 99

Endorphins, endogenous, as pain markers, 421

Endoscopy, in gastroesophageal reflux, 149

Endosomes, intestinal, in host defense, 47

Endothelins

- in enteric nervous system development, 106-107
- in intestinal circulation regulation, 28-29
- in necrotizing enterocolitis, 34-35

Endothelium, dysfunction of, in necrotizing enterocolitis, 33-36

Endotracheal intubation, premedication for, 535-552

Energy

- expenditure of, corticosteroids effects on, 306
- failure of, in hypoxic-ischemic brain injury, 587, 632-634
- requirements of
 - for fetal growth, 228-230
 - for very low birthweight infants, 240-241
 - in infections, 299-301

Enteral feeding

- for short-bowel syndrome, 183-184
- for very low birthweight infants, 237-241
- minimal, intestinal mucosal effects of, 67-68

Enteric nervous system, 97-114

- components of, 98
- development of
 - embryologic, 99-102
 - molecular biology of, 105-109
 - molecular marker studies of, 103-104
 - mutant animal studies of, 103
 - signaling pathways in, 105-108
 - tissue recombination studies of, 102-103
 - transcriptional regulation of, 108-109
 - transgene markers for, 104-105
- disorders of, 98
- immaturity of, 99
- physiology of, 97-98

Enterobacteriaceae, in meningitis, 798

Enterocolitis, necrotizing. *See* Necrotizing enterocolitis.

Enterocytes, apical membrane of, in host defense, 47

Enteroviruses, in central nervous system infections, 809-810

Environmental factors

- in brain injury, in very low birthweight infants, 784-787

- in neurodevelopment, 382-388
- postdischarge, for very low birthweight infants, 787
- Enzymes, in intestinal cells, in host defense, 47
- Epidermal growth factor, gastrointestinal trophic effects of, 79-81
- Epinephrine
 - as pain marker, 419-420
 - for hypoxic-ischemic brain injury, 675-676
- Epithelium and epithelial cells
 - intestinal, in host defense, 45-47, 50-51
 - signaling by, in enteric nervous system development, 108
- Erythroblastosis fetalis, hypoglycemia in, 248
- Erythromycin
 - for gastroesophageal reflux, 152
 - pharmacology of, 122-124
- Erythropoietin
 - deficiency of, in anemia of prematurity, 283-284
 - replacement of, in anemia of prematurity, 287-289
- Esophagitis, in gastroesophageal reflux, 144-145
- Esophagus
 - atresia of, surgical treatment of, 8-9
 - gastric contents reflux into. *See* Gastroesophageal reflux.
- Ethical issues, in pain management, 566-567
- Etomidate, surgical stress response suppression due to, 418
- Ex utero intrapartum therapy, for airway obstruction, 4
- Excitotoxicity
 - in hypoxic-ischemic brain injury, 588-589, 635-636
 - in periventricular leukomalacia, 752
- EXIT (ex utero intrapartum therapy), for airway obstruction, 4
- Extracorporeal membrane oxygenation, stroke in, 706
- Extremely low birthweight infants
 - definition of, 329
 - long-term growth of, 332
 - pain sensitivity and assessment in, 479-480
- Eye infections, cytomegalovirus, 809-810

F

- FABP lipid transporter, 208
- Face, Legs, Activity, Cry, and Consolability, for pain assessment, 473, 476
- Facial expression, in pain assessment, 449-450, 471-473, 482
- Famotidine, pharmacology of, 124-126
- FAT lipid transporter, 208
- FATP lipid transporter, 208
- Fatty acids
 - essential, 264-268. *See also* Long-chain polyunsaturated fatty acids, for very low birthweight infants, 783
 - for bilirubin neurotoxicity, 769
 - for hyperglycemia, 255-256
 - in parenteral nutrition, for very low birthweight infants, 234-236
 - long-chain, 56-57, 76-77
 - metabolic defects of, hypoglycemia in, 253-254
 - short-chain, 75-76
- Feeding. *See also* Formulas; Nutrition.
 - intestinal circulation response to, 31
 - tolerance of, in preterm infants, 316, 318
- Fentanyl
 - adverse effects of, 502
 - clinical efficacy of, 500
 - for fetal surgery, 367
 - for premedication, for endotracheal intubation, 536, 540-541, 544, 549
 - metabolism of, polymorphisms in, 524
 - pharmacodynamics of, 498
 - pharmacokinetics of, 495-496, 519-520
 - surgical stress response suppression due to, 417-418
 - tolerance of, 503, 518
- Fetus
 - consciousness of, 366-367
 - gastrointestinal anomalies in, 2-5
 - intestinal circulation of, basal vascular resistance in, 24-25
 - nutrition in
 - before implantation, 205
 - for cardiovascular health, 203-204
 - for growth, 204-205
 - placental transfer of, 205-208
 - amino acids, 208-213
 - glucose, 207-210
 - in pathologic states, 213-215
 - lipids, 208, 212-213
 - pain in
 - analgesia for, 512-516

- anesthesia for, 366-367
 - brain development and, 361-362, 366-367
 - perception of, 366-367, 512-516
 - stress response in, 383
 - Fever
 - in hypoxic-ischemic brain injury, 642
 - maternal, neonatal encephalopathy and, 609-612
 - Fibrinolysis, periventricular-intraventricular hemorrhage in, 744-745
 - Fibroblast growth factor, gastrointestinal trophic effects of, 82
 - FIC1* gene mutations, in progressive familial intrahepatic cholestasis, 171-172
 - Fish oils, long-chain polyunsaturated fatty acids in, 273-274
 - Fluconazole, for fungal infections, 814
 - Fluid and electrolyte balance, in nutritional assessment, of preterm infants, 322
 - Fluid therapy
 - for hypoxic-ischemic brain injury, 676-678
 - for short-bowel syndrome, 183
 - 5-Fluorocytosine, for fungal infections, 813-814
 - Fluoroscopy, in gastroesophageal reflux, 148
 - Fontanelle, pressure in, in endotracheal intubation, premedication effects on, 539, 544, 547
 - Formulas
 - for cholestasis, 175
 - for preterm infants, 314-317
 - fatty acids in, 266-270, 276
 - post-discharge, 334-336
 - macronutrient composition of, 70-71
 - versus breast milk
 - gastroesophageal reflux and, 150
 - nutritional aspects of, 68-70
 - Foscarnet, for cytomegalovirus infections, 809-810
 - Free radicals
 - in hypoxic-ischemic brain injury, 589-590, 594, 637-638
 - in periventricular leukomalacia, 752
 - Fructose 1,6-diphosphatase deficiency, hypoglycemia in, 251-252
 - Fructose 1,6-diphosphatase aldolase deficiency, hypoglycemia in, 252-253
 - Fructose intolerance, hypoglycemia in, 252-253
 - Fuller Infant Pain Assessment Tool, clinical utility of, 462-463
 - Fundoplication, for gastroesophageal reflux, 7-8, 153
 - Fungal infections, of central nervous system, 813-815
 - Funisitis, periventricular leukomalacia and, 753-754
- ## G
-
- Galactose-1-phosphate uridyl transferase deficiency, hypoglycemia in, 252
 - Ganciclovir, for cytomegalovirus infections, 809-810
 - Ganglion cells
 - absence of, in Hirschsprung's disease, 10-11, 98
 - in enteric nervous system, 98, 101-102
 - Gastric acid, in host defense, 43-44
 - Gastrin, trophic effects of, 77-78
 - Gastrin-releasing peptide, trophic effects of, 78
 - Gastroenterology. *See also* Nutrition.
 - anomalies, 1-21
 - esophageal atresia, 8-9
 - fetal surgery for, 2-5
 - gastroesophageal reflux in, 7-8
 - gastroschisis, 11-12
 - Hirschsprung's disease, 10-11, 98
 - hyperinsulinism, 14-15
 - imperforate anus, 13-14
 - inguinal hernia, 8
 - malrotation, 9-10
 - minimally invasive surgery for, 5-10
 - necrotizing enterocolitis in, 12-13
 - prenatal diagnosis of, 2-5
 - pyloric stenosis, 6-7
 - transplantation in, 15-16
 - cholestasis, 159-180
 - cytokines, 84-85
 - enteric nervous system, 97-114
 - gastroesophageal reflux. *See* Gastroesophageal reflux.
 - glucocorticoids, 83-84
 - growth factors, 79-85
 - hormones, 77-84
 - host defense, 41-51
 - intestinal circulation, 23-39

- key nutrients in, 65-96
 - peptide growth factors, 79-84
 - pharmacology, 115-133
 - short gut, 181-194
- Gastroesophageal reflux, 135-158**
- clinical patterns of, 143-145
 - defense mechanisms for, 140-143
 - definition of, 135
 - diagnosis of, 146-149
 - differential diagnosis of, 145-146
 - embryologic physiology and, 137-138
 - incidence of, 136
 - pathophysiology and pathogenesis of, 136-143
 - physiologic, versus pathologic, 146
 - prevalence of, 136
 - refluxate composition in, 140
 - risk factors for, 136-137
 - surgical treatment of, 7-8
 - treatment of, 149-153
- Gastroschisis, surgical treatment of, 11-12**
- Gastrostomy, for gastroesophageal reflux, 7-8, 153**
- Genetic factors**
- in brain injury, associated with chorioamnionitis, 613
 - in neonatal cholestasis, 170-174
- Gentamicin, for bacterial meningitis, 797-799**
- GER. See Gastroesophageal reflux.**
- Germinal matrix intraventricular hemorrhage. See also Periventricular-intraventricular hemorrhage.**
- neuroimaging in, 831-832
- Gestational age, versus pain response, heart rate variability and, 434-436**
- Gilbert's syndrome, morphine metabolism in, 518**
- GLAST amino acid transporter, 209**
- Glial cell line-derived neurotrophic factor, in enteric nervous system development, 107-108**
- GLT amino acid transporter, 209**
- Glucagon**
- as pain marker, 421
 - for persistent hyperinsulinemic hypoglycemia of infancy, 250
- Glucagon-like peptide 2**
- for short-bowel syndrome, 188-189
 - trophic effects of, 78-79
- Glucocorticoids. See Corticosteroids.**
- Glucokinase defects, in persistent hyperinsulinemic hypoglycemia of infancy, 249-250**
- Glucose**
- extremes of. *See* Hypoglycemia; Hypoglycemia.
 - homeostasis of, 245-246
 - metabolism of, 652-654
 - monitoring of, in nutritional assessment, of preterm infants, 322
 - parenteral
 - for hypoglycemia, 667-668
 - in infants of diabetic mothers, 248
 - in small-for-gestational-age infants, 249
 - for hypoxic-ischemic brain injury, 679
 - for infections, 301
 - for very low birthweight infants, 233-234
 - placental transfer of, 207-210, 214
 - supplements for, for preterm infants, 316-317
 - utilization of, hypoglycemia and, 655-656
- Glucose-6-phosphatase deficiency, hypoglycemia in, 251**
- Glucose intolerance**
- in very low birthweight infants, 233-236
 - suboptimal intrauterine growth and, 204-205
- Glucose transporters, 207-210, 655**
- Glutamate**
- accumulation of
 - in hypoxic-ischemic brain injury, 588-589, 594, 841-842
 - in periventricular leukomalacia, 752
 - in hypoglycemia, 657-658
- Glutamate dehydrogenase defects, in persistent hyperinsulinemic hypoglycemia of infancy, 249-250**
- Glutamine**
- for infections, 302
 - in nutrition, 52-56, 71-73
- Glutathione peroxidase deficiency, in hypoxic-ischemic brain injury, 590**
- Glycocalyx, intestinal, in host defense, 44-45**
- Glycogen storage diseases, hypoglycemia in, 251**
- Glycopyrrolate, for premedication, for endotracheal intubation, 543**
- Goblet cells, in host defense, 46**

Gram-negative organisms, in meningitis, 798-799

Growth

- brain, neuroimaging studies of
 - in impairment, 835-837
 - normal, 825-830
- catch up, in preterm infants, 328-329
- charts for, in nutritional assessment, of preterm infants, 318-321
- corticosteroids effects on, 303-305
- in congenital heart defects, 340
- intrauterine
 - adult glucose abnormalities and, 204-205
 - charts for, 318-321
 - normal mechanisms of, 205-207
 - nutritional requirements for, 228-230
 - rate of, 318
 - retardation of, 213-215, 329
 - in diabetes mellitus, 204-205
 - nutritional interventions for, 339
 - postnatal growth and, 338-339
 - stroke in, 702-703
 - long-chain polyunsaturated fatty acids effects on, 274-275

Growth factors, gastrointestinal trophic effects of, 79-82

Growth hormone

- as pain marker, 422
- deficiency of, hypoglycemia in, 250-251
- gastrointestinal trophic effects of, 83

Gut-specific amino acids, in nutrition, 71-74

Gut trophic factor (glutamine), in nutrition, 52-56, 71-73

H

Halothane

- for premedication, for endotracheal intubation, 539, 544
- surgical stress response suppression due to, 417

Heart, congenital defects of

- growth failure in, 340
- stroke in, 707

Heart rate variability, 427-443

- aperiodic, 430
- at rest, 429
- autonomic influences on, 430-431
- decoding of, 428-431
- frequency domain signals in, 430, 436

- in endotracheal intubation, premedication effects on, 538-542, 544-549
- in pain assessment
 - baseline for, 437
 - composite multivariate scales for, 438
 - methodological issues in, 436-437
 - opioid effects on, 437-438
 - patterns of, 432-436
 - physiologic interpretation of, 437-438
 - postoperative, 474
 - respiration effects on, 429-430, 435
 - short-term, 429, 437
 - time domain signals in, 429-430, 436
 - transfer function analysis of, 431
 - unrelated to pain, in intensive care setting, 431-432

Hemochromatosis, cholestasis in, 173-174

Hemolysis, bilirubin neurotoxicity in, 771

Hemorrhage

- intracranial, neuroimaging in, 846-847
- intraventricular. *See also* Periventricular-intraventricular hemorrhage, neuroimaging in, 831-832

Hemorrhagic-ischemic brain injury, in preterm infants, 743-761

- in periventricular-intraventricular hemorrhage, 743-750
- in periventricular leukomalacia, 750-755

Hepatitis, neonatal, cholestasis in, 170

Hepatobiliary transporter defects, cholestasis in, 171-172

Hepatocyte(s), disorders of, cholestasis in, 169-171

Hepatocyte growth factor, gastrointestinal trophic effects of, 82

Hernia

- diaphragmatic, prenatal versus postnatal, 3-4
- inguinal, surgical repair of, 8

Herpes simplex virus, in central nervous system infections, 806-809

Hippocampal injury, in very low birthweight infants, 779-780

Hirschsprung's disease

- pathophysiology of, 98
- surgical treatment of, 10-11

Histamine₂ blockers

- for gastroesophageal reflux, 152
- pharmacology of, 124-126

- HIV infection, of central nervous system, 811-812
- Host defense, of gastrointestinal tract, 41-51
 breast milk components in, 42-43
 cytokines and chemokines in, 49-51
 enterocyte apical membrane in, 47
 epithelium in, 45-47
 gastric acid in, 43-44
 glycocalyx in, 44-45
 intracellular organelles and enzymes in, 47
 lactoferrin in, 48-49
 M cells in, 46
 microvilli in, 47
 motility in, 43
 mucus in, 44-45
 pancreatobiliary secretions in, 43-44
 subepithelial cells in, 48
- hTAUT amino acid transporters, 209
- Human immunodeficiency virus, in central nervous system infections, 811-812
- Human milk. *See* Breast milk; Breastfeeding.
- Human parvovirus B19, in central nervous system infections, 812-813
- Hydrocephalus, in intraventricular hemorrhage, neuroimaging in, 831-832
- Hydrogen peroxide, in hypoxic-ischemic brain injury, 589-590
- Hydrops, fetal
 in congenital cystic adenomatoid malformation, 4
 in sacrococcygeal teratoma, 4-5
 stroke in, 701
- Hyperalgesia, in vulnerable neonates, 375, 377
- Hyperbilirubinemia. *See* Bilirubin, neurotoxicity of; Cholestasis.
- Hypercapnia, permissive, in hypoxic-ischemic brain injury, 678-679
- Hyperemia, postprandial, in intestinal circulation, 31
- Hyperglycemia
 maternal or fetal, placental glucose transport in, 214-215
 neonatal, 246, 254-256
- Hyperinsulinemia
 congenital, 14-15
 in infants of diabetic mothers, 247-248
 in persistent hyperinsulinemic hypoglycemia of infancy, 249-250
- Hypertension
 early nutrition impact on, 204
- maternal, fetal and newborn stroke in, 695-696
- pregnancy-induced, periventricular-intraventricular hemorrhage and, 747
- Hyperthermia, in hypoxic-ischemic brain injury, 642
- Hypocarbica, periventricular leukomalacia and, 753-754
- Hypoglycemia
 maternal or fetal, placental glucose transfer in, 207, 209-210
 neonatal, 247-254
 adverse effects of, 246
 alternative substrates to glucose and, 654-655
 asymptomatic, 651
 brain injury in
 biochemical alterations in, 656-659
 hypoxic-ischemic, 658, 660-661
 neuroimaging in, 663-665
 outcome of, 666-667
 pathology of, 665-666
 resistance to, 650
 seizures in, 661
 symptoms of, 662-663
 classic transitional, 662
 clinical aspects of, 661-662
 definition of, 247, 649-652
 early transitional, 661
 glucose transporters and, 655
 hyperinsulinemic, 14-15
 in amino acid metabolic defects, 254
 in Beckwith-Wiedemann syndrome, 248
 in carbohydrate metabolic disorders, 251-253
 in enzyme deficiencies, 251-254
 in erythroblastosis fetalis, 248
 in fatty acid metabolic defects, 254-255
 in fructose 1,6-diphosphatase deficiency, 251-252
 in fructose 1-phosphate aldolase deficiency, 252-253
 in galactose-1-phosphate uridylyl transferase deficiency (galactosemia), 252
 in glycogen storage diseases, 251
 in hormone deficiencies, 250-251
 in infants of diabetic mothers, 247-248
 in persistent hyperinsulinemic hypoglycemia of infancy, 249-250
 in phosphoenolpyruvate carboxykinase deficiency, 252

- in pyruvate carboxylase deficiency, 252
 - incidence of, 650-652
 - neuroimaging in, 663-665, 844-846
 - normal glucose metabolism and, 652-654
 - outcome of, 666-667
 - pathophysiology of, 655-656
 - preterm, 255
 - risk factors for, 247-254
 - secondary associated, 661-662
 - severe recurrent, 662
 - signs and symptoms of, 247
 - small-for-gestational age, 248-249
 - symptoms of, 662-663
 - term, 247-251
 - treatment of, 667-668
 - Hypoketonemia, in fatty acid metabolic defects, 253-254
 - Hypotension
 - in hypoxic-ischemic brain injury, 838
 - opioid-induced, 502
 - periventricular-intraventricular hemorrhage in, 744
 - Hypothermia, for hypoxic-ischemic brain injury, 683-685, 843
 - animal studies of, 625-632
 - brain thermal regulation and, 638-640
 - clinical implications of, 643-644
 - clinical trials of, 643-644
 - delayed, 630-632
 - duration of, 628
 - extent of, 628
 - historical perspective of, 624-625
 - immediate, 629-630
 - methods for, 640-642
 - mild to moderate, 628-632
 - modest to moderate, 625-628
 - pathogenic mechanisms and, 632-638
 - time of initiation of, 627
 - Hypohyoxemia, of prematurity, brain injury in, 781-782
 - Hypotonia, in stroke, 707-708
 - Hypoxanthine, accumulation of, in hypoxic-ischemic brain injury, 590
 - Hypoxemia, intestinal circulation response to, 30-31
 - Hypoxia, bilirubin neurotoxicity in, 770
 - Hypoxic-ischemic brain injury
 - animal studies of, 586, 625-632
 - hyperthermia effects on, 642
 - hypoglycemia with, 658, 660-661
 - neuroimaging in, 837-844
 - pathogenesis of, 585-602, 632-638, 837-841
 - animal models of, 586
 - apoptosis in, 594-595
 - biochemical cascades in, 588-593
 - calcium accumulation in, 589
 - clinical implications of, 594-596
 - cytokines in, 591-592, 594
 - energy failure in, 587, 632-634
 - excitotoxicity in, 588-589, 635-636
 - free radicals in, 589-590, 637-638
 - hypoxia in, 586-587
 - infections in, 587
 - initiating mechanisms in, 586-587
 - ischemia in, 587
 - lipid mediators in, 592-593
 - nitric oxide in, 590-591
 - oligodendrocyte vulnerability in, 593-594
 - temperature effects on, 623-648. *See also* Hypothermia, for hypoxic-ischemic brain injury.
 - animal studies of, 625-632
 - clinical implications of, 642-644
 - historical perspective of, 624-625
 - in fever, 642
 - mechanisms of, 632-638
 - regulation of, 638-640
 - treatment of, 673-690, 843
 - based on pathogenic mechanisms, 595-596
 - fluid therapy in, 676-678
 - hypothermia in. *See* Hypothermia, for hypoxic-ischemic brain injury.
 - in delivery room, 673-676
 - in meconium staining, 675
 - neuroprotective, 679-685
 - oxygen therapy for, 673-674
 - pharmacologic, 675-676, 679-683
 - post resuscitation, 677-685
 - temperature control in, 675
 - ventilation in, 678-679
-
- I**
- Imaging, of brain. *See* Neuroimaging; *specific modalities.*
 - Immune globulin, intravenous, for bacterial meningitis, 799
 - Immunocytochemistry, in animal studies of pain, 408-409
 - Immunoglobulins, intestinal, in host defense, 48

- Immunonutrients, 51-59
 arginine, 56
 butyric acid, 58-59
 fatty acids, long-chain, 56-57
 glutamine, 52-56
 nucleotides, 57
 prebiotics, 57-58
 probiotics, 57-58
- Imperforate anus, surgical treatment of, 13-14
- Indomethacin
 for periventricular-intraventricular hemorrhage, 748
 maternal, neonatal effects of, 514
- Infant-provider interaction, in very low birthweight infants, neurodevelopmental effects of, 784-785
- Infants of diabetic mothers, hypoglycemia in, 247-248
- Infarction, brain. *See* Stroke.
- Infections
 intrauterine, fetal and newborn stroke in, 698
 maternal
 antibiotics for, neurodevelopmental effects of, 726-731
 hypoxic-ischemic brain injury in, 587
 neonatal
 bilirubin neurotoxicity in, 767, 770-771
 central nervous system, **797-824**
 bacterial, 797-799, 802
 fungal, 813-815
 mycobacterial, 815
 mycoplasma, 802-804
 protozoan, 815-818
 spirochetal, 800-801, 804-806
 viral, 806-813
 cholestasis in, 169-170
 metabolic effects of, 296-302
 energy expenditure, 299-301
 functions of, 296
 implications of, for feeding, 301-302
 lipids, 300-301
 micronutrients, 300-302
 proteins, 297-299, 301
 as pain marker, 421
 excess of. *See* Hyperinsulinemia.
 for hyperglycemia, 255
 in parenteral nutrition, for very low birthweight infants, 234-236
 resistance to, suboptimal intrauterine growth and, 204-205
- Insulin-like growth factors
 gastrointestinal trophic effects of, 81-82
 in fetal growth, 214
- Intelligence, in stroke, 714-715
- Intensive care, heart rate variability in, 431-432
- Interferon- γ , gastrointestinal trophic effects of, 85
- Interleukin(s)
 gastrointestinal trophic effects of, 85
 in host defense, 50-51
 in hypoxic-ischemic brain injury, 591-592
 in periventricular leukomalacia, 753
- Intestinal circulation, **23-39**
 adrenergic nerve stimulation effects on, 31
 arterial pressure effects on, 30
 basal vascular resistance in, 24-29
 in fetus, 24-25
 in first postnatal month, 25-26
 mechanisms of, 26-29
 diving reflex theory and, 32-33
 feeding effects on, 31
 hypoxemia effects on, 30-31
 necrotizing enterocolitis and, 32-36
 pathophysiology of, 32-36
 vascular responses in, 29-31
- Intestine. *See also* Colon; Small intestine.
 atrophy of, in parenteral nutrition, 66-68
 circulation of. *See* Intestinal circulation.
 malrotation of, surgical treatment of, 9
- Intracranial hemorrhage, neuroimaging in, 846-847
- Intracranial pressure, in endotracheal intubation, premedication effects on, 540, 546
- Intraepithelial lymphocytes, in host defense, 45-46
- Intrauterine growth. *See* Growth, intrauterine.
- Intraventricular hemorrhage. *See also* Periventricular-intraventricular hemorrhage.
 neuroimaging in, 831-832
- Intubation, endotracheal, premedication for, **535-552**

- Iron status, of premature infants
 at birth, 284
 erythropoietin replacement effects on,
 287-289
 evaluation of, 285-286
 iron supplementation effects on, 288-289
 long-term, 289-290
 metabolism of, 285
 requirements of, 284-285
 transfusion effects on, 286-287
- Ischemia, brain injury in. *See* Hemorrhagic-
 ischemic brain injury; Hypoxic-ischemic
 brain injury.
- Islet cells, partial excision of, for
 hyperinsulinemia, 15
- Isoflurane, for premedication, for endotracheal
 intubation, 544

J

- Jaundice. *See* Bilirubin, neurotoxicity
 of; Cholestasis.
- Junctional complex, of intestinal epithelium, in
 host defense, 46

K

- Kangaroo care, for very low birthweight
 infants, 785
- Kasai procedure, for biliary atresia, 165-167
- Keratinocyte growth factor, gastrointestinal
 trophic effects of, 82
- Kemisterus. *See* Bilirubin, neurotoxicity of.
- Ketamine, for premedication, for endotracheal
 intubation, 540, 544
- Ketone bodies, as cerebral metabolism fuel,
 654, 660-661
- Kidney
 dysfunction of, in hypoxic-ischemic brain
 injury, 677-678
 polycystic disease of, cholestasis in, 167
- Kynurenic acid, for hypoxic-ischemic brain
 injury, 680-681

L

- Labor and delivery
 fetal and newborn stroke during,
 704-705
 periventricular-intraventricular
 hemorrhage and, 747-748
- Lactic acid
 as cerebral metabolism fuel, 654

- formation of, opioid-induced, 840-841
- Lactobacillus*, for short-bowel syndrome, 189
- Lactoferrin, in host defense, 48-49
- Language disorders, in stroke, 714-715
- Lansoprazole, pharmacology of, 127
- Laparoscopic surgery
 for gastroesophageal reflux, 7-8
 for Hirschsprung's disease, 11
 for imperforate anus, 14
 for inguinal hernia, 8
 for malrotation, 9
 for pyloric stenosis, 6-7
- Laryngeal reflex, for reflux protection, 140
- LAT amino acid transporters, 208
- LCPUFAs. *See* Long-chain polyunsaturated
 fatty acids.
- Legal issues, in pain management, 566-567
- Leptomenigitis, syphilitic, 800-801,
 804-805
- Leukomalacia, periventricular. *See*
 Periventricular leukomalacia.
- Leukotrienes, in hypoxic-ischemic brain injury,
 592-593
- Leukovorin, for toxoplasmosis, 816-817
- Levobupivacaine, maternal, neonatal effects
 of, 514
- Light conditions, in neonatal intensive care
 unit, neurodevelopmental effects of,
 786-787
- Linoleic acid, in nutrition
 adverse effects of, 274-275
 deficiency of, 266
 in breast milk, 266
 in formulas, 266
 metabolism of, 267
 sources of, 265-266
 structure of, 264
- α -Linoleic acid, in nutrition
 in formulas, 266-267
 metabolism of, 267
 sources of, 265-266
 structure of, 264
 visual function and, 268
- Lipase, in fat digestion, 263-264
- Lipid(s). *See also* Fatty acids; Long-chain
 polyunsaturated fatty acids.
 absorption of, 263-264
 digestion of, 262-263
 for hyperglycemia, 255-256
 for preterm infants, 315-317

- in parenteral nutrition, for very low birthweight infants, 236-237
 - mediators of, in hypoxic-ischemic brain injury, 592-593
 - metabolism of, 264
 - corticosteroids effects on, 307
 - in infections, 300-301
 - placental transfer of, 208, 212-213
 - requirements of, 261-262
 - structured, for infections, 302
 - structures of, 261-262
- Liver**
- biopsy of, in biliary atresia, 166
 - cholestatic disease of. *See* Cholestasis.
 - fibrosis of, cholestasis in, 167
 - transplantation of, for gastrointestinal anomalies, 15-16
- Liverpool Infant Distress Scale**, 472, 474, 476
- Local anesthesia, maternal, neonatal effects of**, 514
- Long-chain polyunsaturated fatty acids, in nutrition**, 261-281
- adverse effects of, 274-275
 - deficiency of, 266-267
 - importance of, 264
 - in breast milk, 266
 - in formulas, 276
 - intake of
 - cognitive-behavioral development and, 270-273
 - visual function and, 268-270
 - medium-chain fat absorption and, 264
 - metabolism of, 264-265, 267-268
 - sources of, 265-266, 273-274
 - structures of, 266-267
 - supplementation with, 273-274, 276
- Loperamide, for short-bowel syndrome**, 186
- Low birthweight infants**. *See also* Extremely low birthweight infants.
- definition of, 329
 - long-term growth of, 332
- Lung, congenital cystic adenomatoid malformation of, fetal surgery for**, 4
- Lyme disease, of central nervous system**, 805-806
- Lymphocytes, intraepithelial, in host defense**, 45-46
- Lymphocytic choriomeningitis virus, in central nervous system infections**, 813
- M**
- M cells, intestinal, in host defense**, 46
- Macrosomia, glucose transfer in**, 214
- Magnesium sulfate**
 - for hypoxic-ischemic brain injury, 682
- maternal, neurodevelopmental effects of**, 731-733
- Magnetic resonance angiography, in stroke**, 710
- Magnetic resonance imaging**
 - in brain injury
 - advantages of, 825-826
 - diffusion-weighted, 827-828, 836-837
 - hypoglycemic, 844-846
 - in growth and development impairment, 835-837
 - in intracranial hemorrhage, 846-847
 - in intraventricular hemorrhage, 831-832
 - in periventricular leukomalacia, 832-835
 - three-dimensional, 827
 - versus normal development, 825-830
 - in stroke, 708, 710, 844
- Magnetic resonance spectroscopy, in brain injury**, 829-830, 840-843
- Malabsorption, in short-bowel syndrome**, 182
- Malaria, congenital**, 818
- Malnutrition, maternal, offspring nutritional abnormalities related to**, 203-205, 213-214
- Malrotation, intestinal, surgical treatment of**, 9
- Manometry, in gastroesophageal reflux**, 138-140, 148-149
- Maple syrup urine disease, hypoglycemia in**, 253
- Mash1 protein, of enteric nervous system development**, 109
- Massage therapy, for very low birthweight infants**, 785
- Mast cells, intestinal, in host defense**, 48
- Maternal influences, on neurodevelopment**, 364, 384-388. *See also* Neurodevelopmental effects, of maternal therapies.
- Measles, of central nervous system**, 812
- Mechanical ventilation**
 - pain assessment in, 479-480
 - periventricular-intraventricular hemorrhage and, 748
- Meconium staining, in asphyxia, treatment of**, 675

- Meningitis
bacterial, 797-799, 802
fungal, 813
stroke in, 705
syphilitic, 800-801, 804-805
tuberculous, 815
- Mental retardation, postoperative pain assessment in, 480-485
- Meperidine, pharmacokinetics of, 495
- Mesenchymal cells, in enteric nervous system development, 108
- Mesoderm, enteric nervous system derived from, 99
- Metabolic acidosis, bilirubin neurotoxicity in, 766, 770
- Methohexital, for premedication, for endotracheal intubation, 548-549
- N-Methyl-D-aspartate receptors
antagonists to, for hypoxic-ischemic brain injury, 680-681
in fetal brain development, pain effects on, 361
- Methylxanthines
brain injury due to, 781
gastrointestinal effects of, 127
- Metoclopramide
for gastroesophageal reflux, 151
pharmacology of, 117-119
- Microvilli, intestinal, in host defense, 47
- Midazolam
for premedication, for endotracheal intubation, 536, 545, 549
surgical stress response suppression due to, 418
- Milk, human. *See* Breast milk; Breastfeeding.
- Minerals
deficiencies of, in infections, 300-302
in formulas, for preterm infants, 337
- Minimal enteral feeding, intestinal mucosal effects of, 67-68
- MK-801, for hypoxic-ischemic brain injury, 680-681
- Modified Behavioral Pain Scale, 475
- Modified Infant Pain Scale, 473-474, 476-477
- Morphine
adverse effects of, 501-502
clinical efficacy of, 499-500
dosage for, 504-505, 515
effects of, 514-515
for premedication, for endotracheal intubation, 536
maternal, neonatal effects of, 513-514, 516-517
metabolism of, polymorphisms in, 522-524
pharmacodynamics of, 496-497
pharmacokinetics of, 494-495, 514-515, 518-519
surgical stress response suppression due to, 417
withdrawal from, 503
- Motility, gastrointestinal
enteric nervous system in. *See* Enteric nervous system.
in host defense, 43
measurement of, in gastroesophageal reflux, 149
- Mucus, intestinal, in host defense, 44-45
- Multiple gestation, stroke in, 701-702
- Muscle rigidity, opioid-induced, 502
- Music therapy, for very low birthweight infants, 786
- Mutation studies, of enteric nervous system development, 103
- Mycoplasma hominis*, in central nervous system infections, 802-804
- Mydriatics, gastrointestinal effects of, 127-128
- Myelination, in brain growth and development, 826-828, 835-837
- Myelomeningocele, fetal surgery for, 5
- Myo-inositol, increase of, in hypoxic-ischemic brain injury, 842-843
- Myogenic response, in intestinal circulation regulation, 28
- N**
- Naloxone, for opioid reversal, 500, 502
- Narcotics. *See* Opioids.
- Nex transcription factor, of enteric nervous system development, 109
- Necrotizing enterocolitis
intestinal circulation and, 32-36
prevention of, nutritional practices for, 238-239
surgery for, 12-13
pain severity in, 470-471
short-bowel syndrome after, 182

- Needlestick pain, in vulnerable neonates, animal models of, 398
- Neonatal Facial Coding System, for pain assessment, 471, 478
- Neonatal Infant Pain Scale, 475
- Neonates, vulnerable, pain in. *See* Pain, in vulnerable neonates.
- Nerve ligation, in vulnerable neonates, animal models of, 399
- Nervous system, enteric. *See* Enteric nervous system.
- Neural crest, enteric nervous system derived from, 99-104
- Neuroborreliosis, 805-806
- Neurodevelopmental effects
 of dietary fatty acids and, 270-273
 of hypoglycemia, 666-667
 of maternal therapies, **723-741**
 antibiotics, 726-731
 corticosteroids, 733-735
 phenobarbital, 736
 surrogate markers of, 725-726
 thyrotropin-releasing hormone, 735-736
 tocolytics, 731-733
 vitamin K, 736
 of pain
 long-term outcome of, **373-394**
 altered pain response, 380-382
 cerebral blood flow autoregulation immaturity, 380
 environmental factors in, 382-388
 hyperalgesia, 375-377
 intrinsic factors in, 382-388
 low pain threshold, 375
 model of, 376
 neurologic deficits, 378-380
 schematic summary of, 374
 sensitization, 375, 377
 neuronal mechanisms in, **357-372**
 behavioral, 357-359
 imaging studies of, 359-360
 immaturity, 361-362
 in fetus, 366-367
 intensive care unit environment, 363-364
 maternal influences on, 364, 384-388
 repetitive, 364-366
 of periventricular-intraventricular hemorrhage, 748-749
 of periventricular leukomalacia, 755
 of stroke, 713-715
- Neuroimaging
 in brain injury, **825-852**
 hypoglycemic, 663-665, 844-846
 hypoxic-ischemic, 837-844
 in focal ischemic infarction, 844
 in full-term infants, 837-847
 in growth and development impairment, 835-837
 in intracranial hemorrhage, 846-847
 in intraventricular hemorrhage, 831-832
 in periventricular leukomalacia, 832-835
 in preterm infants, 831-837
 in stroke, 844
 versus normal development, 825-830
 in pain-related neurodevelopmental deficits, 359-360
- Neurologic disorders
 in cytomegalovirus infections, 808-809
 in herpes simplex virus encephalitis, 808-809
 in HIV infection, 811
 in stroke, 707-708, 713-715
 in toxoplasmosis, 815-817
 postoperative pain assessment in, 480-485
- Neuron(s), subplate, organizational disturbance in, in very low birthweight infants, 778-779
- Neurotensin, gastrointestinal trophic effects of, 79
- Neurotransmitters, impairment of, in hypoxic-ischemic brain injury, 594, 841-842
- Nicardipine, for hypoxic-ischemic brain injury, 681
- Nitric oxide
 deficiency of, in necrotizing enterocolitis, 34-35
 for hypoxic-ischemic brain injury, 678
 in hypoxic-ischemic brain injury, 590-591
 in intestinal circulation regulation, 27
- Nitrogen balance, in infections, 297-299
- Nitrous oxide
 for premedication, for endotracheal intubation, 544
 surgical stress response suppression due to, 418
- Noise control, for very low birthweight infants, 785-786

- Non-Communicating Children's Pain Checklist, 481-484
- Norepinephrine
as pain marker, 419-420
in fetus, 512
constrictor activity of, in necrotizing enterocolitis, 34
- Nucleotides, in nutrition, 57, 74-75
- Nursing Assessment of Pain Intensity, 472, 475-476
- Nutrition, 65-77
aggressive
description of, 227
enteral, 237-241
parenteral, 230-237
arginine in, 56, 73
assessment of, in preterm infants, 318-324
breast milk in
components of, in gastrointestinal host defense, 42-43
for gastroesophageal reflux, 150
versus formula, 68-70
butyric acid in, 58-59, 75-76
deficiencies in, in short-bowel syndrome, 187
enteral, for short-bowel syndrome, 183-184
fatty acids in
long-chain, 56-57, 76-77
short-chain, 75-76
for cholestasis, 174-175
for gastroesophageal reflux, 150-151
for preterm infants, 313-326
for very low birthweight infant, 225-244, 783
glucose extremes and, 245-260
glutamine in, 52-56, 71-73
gut-amino acids in, 71-74
immunonutrients in, 51-59
importance of, 203-223
for cardiovascular system, 203-204
for growth, 204-205
placental transfer and, 205-208
amino acids, 208-213
glucose, 207-210
in pathologic states, 213-215
lipids, 208, 212-213
postnatal, 215-216
thrifty hypothesis and, 203-205, 328-329
in anemia of prematurity, 283-294
long-chain polyunsaturated fatty acids in, 261-281
macronutrient composition in, 70-71
metabolism in, 295-312
infection effects on, 296-302

- postnatal steroids effects on, 302-307
mode of administration of, 66-68
nucleotides in, 57, 74-75
parenteral. *See* Parenteral nutrition.
postdischarge, 327-344
prebiotics in, 57-58
probiotics in, 57-58

O

- Obesity, breastfeeding protection against, 215-216
- Objective Pain Scale, 473-474, 476
- Oligodendrocytes, vulnerability of
in fetus, 362
in hypoxic-ischemic brain injury, 593-594
in periventricular leukomalacia, 752
- Omega-fatty acids. *See* Long-chain polyunsaturated fatty acids.
- Omeprazole, pharmacology of, 126-127
- Opioids
changing attitudes toward, 557
for fetal surgery, 367
heart rate variability and, 437-438
pharmacokinetics of, 516-517
pharmacology of, 493-509, 516-517
administration, 504-505
adverse effects, 500-504
clinical efficacy, 498-500
dosage, 504-505
pharmacodynamics, 496-498
pharmacokinetics, 494-496
tolerance, 503, 518
withdrawal, 503
receptors for, polymorphisms in, 525
surgical stress response suppression due to, 417-418
- Organelles, in intestinal cells, in host defense, 47
- Ornithine, in nutrition, 73
- Osteopenia, laboratory studies for, in nutritional assessment, of preterm infants, 323
- Oxidative phosphorylation, impairment of, in hypoxic-ischemic brain injury, 841
- Oxygen consumption, measurement of, in infections, 299
- Oxygen free radicals
in hypoxic-ischemic brain injury, 589-590, 594, 637-638
in periventricular leukomalacia, 752

Oxygen tension

- in pain assessment, postoperative, 474
- transcutaneous, in endotracheal intubation, premedication effects on, 540-541, 546

Oxygen therapy, for hypoxic-ischemic brain injury, 673-674

P

Paediatric Pain Profile, 482-484

Pain

- in fetus. *See* Fetus, pain in.
- in vulnerable neonates
 - assessment of
 - biologic markers for, 415-425
 - body language in, 450
 - challenges of, 445-457
 - clinical significance of, 459-468
 - crying in, 449
 - facial activity in, 449-450
 - heart rate variability in, 427-443
 - physiologic activity in, 450-451
 - postoperative, 469-491
 - clinical significance of, 459-468
 - ethical issues in, 566-567
 - experience of, 447-448
 - expression of, 448-449, 451-453
 - failure to express, 449-450, 453-454
 - in endotracheal intubation, 535-552
 - in sleep, heart rate in, 433
 - learning about, 565
 - legal issues in, 566-567
 - long-term consequences of, 373-394
 - animal models of, 395-414
 - low threshold for, 375
 - management of. *See also* Analgesia; Anesthesia; Opioids; *specific agents*, advocacy for, 559-560
 - beliefs about, 454
 - changing practice of, 556-558
 - clinical significance of, 459-468
 - effects of, 511-534
 - opioids in, 493-509, 516-517
 - parents involvement in, 559-560
 - public pressure effects on, 562

resistance to changes in, 563-565

safety of, 558

standards of care for, 565-567

memory of, 448

neurodevelopment and, animal models of, 357-372

perception of

Anand research on, 561-562

beliefs about, 447-448,

453-454, 556-558

in circumcision, heart rate in, 433-434

physiologic activity in, 450-451

postoperative, assessment of,

469-491

prevalence of, 374, 554-555

procedures causing, 558

reduction of, 554-555

repetitive

animal studies of, 395-414

long-term consequences

of, 409-411

outcome measures for,

399-401

paradigms used in,

397-399

rat pup choice for, 397

summary of, 402-409

value of, 396-397

neurodevelopmental effects

of, 364-366

response to, alterations of,

380-382

sensitization to, 375, 377

social context of, 553-570

twins, 513

versus other adverse states, 451

Pain Assessment Tool, 472, 474-476, 480

Pain Evaluation Scale for Cerebral Palsy, 481-484

Pain Observation Scale for Young Children, 473-476

Pancreas, secretions of, in host defense, 43-44

Pancreatectomy, subtotal or partial

- for hyperinsulinemia, 15
- for persistent hyperinsulinemic hypoglycemia of infancy, 250

Pancuronium

- for muscle rigidity, opioid-induced, 502
- for premedication, for endotracheal intubation, 539-541, 544

Parenteral nutrition

- cholestasis associated with, 174, 187
- for hyperglycemia, 255-256

- for infections, 301
- for short-bowel syndrome, 184-187, 191
- for very low birthweight infants, 230-237
- hyperglycemia in, 246
- intestinal mucosal effects of, 66-68
- Parents
 - in neonatal pain management decisions, 564
 - pain assessment measure for, 485-487
- Parvovirus B19, in central nervous system infections, 812-813
- Pax2 transcription factor, of enteric nervous system development, 109
- Penicillin(s), for bacterial meningitis, 797
- Penicillin G, for syphilis, 800-801
- Pentazocine, maternal, neonatal effects of, 513-514, 516
- Peptide YY, trophic effects of, 78-79
- Perfusion pressure, reduction of, intestinal circulation response to, 30
- Peritoneal drainage, for necrotizing enterocolitis, 12-13
- Periventricular-intraventricular hemorrhage, 743-750
 - clinical features of, 746-747
 - incidence of, 743-744
 - neuropathology of, 744
 - outcome of, 749-750
 - pathogenesis of, 744-746
 - prevention of, 747-749
 - white matter injury in, 746
- Periventricular leukomalacia, 750-755
 - clinical features of, 753-754
 - description of, 750
 - neuroimaging in, 832-835
 - neuropathology of, 750-751
 - outcome of, 755
 - pathogenesis of, 751-753
 - prevention of, 754-755
- Peroxidation, lipid, in hypoxic-ischemic brain injury, 592-593
- Persistent hyperinsulinemic hypoglycemia of infancy, 249-250
- Pethidine
 - for premedication, for endotracheal intubation, 542, 549
 - maternal, neonatal effects of, 513-514
- Peyer's patches, in host defense, 48
- pH measurement, in gastroesophageal reflux, 147-148
- Pharmacodynamics and pharmacokinetics. *See specific drugs.*
- Pharmacology, of gastrointestinal tract, 115-133
 - adverse drug effects, 127-128
 - developmental influences on, 116-117
 - prokinetic agents, 117-126
 - proton pump inhibitors, 126-127
- Phenobarbital
 - for hypoxic-ischemic brain injury, 681-682
 - for periventricular-intraventricular hemorrhage, 747
 - maternal, neurodevelopmental effects of, 736
- Phosphate, in formulas, for preterm infants, 337
- Phosphoenolpyruvate carboxykinase deficiency, hypoglycemia in, 252
- Phototherapy, for bilirubin neurotoxicity, 769
- Phox2b transcription factor, of enteric nervous system development, 109
- Placenta
 - bypass with, during ex utero intrapartum therapy, 4
 - disorders of, fetal and newborn stroke in, 697-698
 - nutrient transfer in, 205-208
 - amino acids, 208-213
 - energy costs of, 206-207
 - glucose, 207-210
 - in pathologic states, 213-215
 - lipids, 208, 212-213
- Platelet-activating factor, in hypoxic-ischemic brain injury, 592-593
- Pleconaril, in enteroviral infections, 810
- Polycythemia, with hyperviscosity, stroke in, 705-706
- Portoenterostomy (Kasai procedure), in biliary atresia, 165-167
- Postoperative pain, 469-491
 - assessment of
 - in cognitive impairment, 480-485
 - in critical illness, 479-480
 - in neurologic impairment, 480-485
 - instruments for, 471-478
 - parent involvement in, 485-487
 - timing of, 478
 - concurrent medical conditions and, 470-471
 - versus surgery type, 470-471

- Postoperative Pain Measure for Parents, 485-487
- Postoperative Pain Scale, 472, 474, 476
- Postprandial hyperemia, in intestinal circulation, 31
- Posture, in gastroesophageal reflux management, 150
- Potassium channel defects, in persistent hyperinsulinemic hypoglycemia of infancy, 249-250
- Pre-eclampsia, fetal and newborn stroke in, 695-696
- Pre-Verbal, Early Verbal Pediatric Pain Scale, 473, 475-476
- Prebiotics, as immunonutrients, 57-58
- Prednisone, for toxoplasmosis, 816-817
- Pregnancy, analgesia in, neonatal effects of, 513-514, 516
- Premature Infant Pain Profile, 461-462, 472, 474-475, 480
- Premature rupture of membranes, antibiotics for, neurodevelopmental effects of, 730-731
- Premedication, for endotracheal intubation, 535-552
- Prenatal diagnosis, of gastrointestinal anomalies, 2-5
- Pressure-flow autoregulation, in intestinal circulation, 30
- Preterm infants
 anemia of. *See* Anemia of prematurity.
 bilirubin neurotoxicity in, 771-772
 brain injury in, neuroimaging in, 831-837
 cerebral palsy in, chorioamnionitis related to, 606-608
 classification of, 329
 glucose homeostasis in, 246
 growth of, 329-333
 catch up, 328-329
 long-term, 332-333
 hemorrhagic-ischemic brain injury in, 743-761
 hypoglycemia in, 254
 infections in, nitrogen balance in, 299
 neurodevelopment of, maternal therapy effects on, 723-741
 nutrition for, 313-326
 assessment of, 318-324
 anthropometric measurements in, 318
 growth charts in, 318-321
 laboratory indices in, 322-324
 weight gain rate in, 321-322
 feeding tolerance and, 316, 318
 goals of, 313
 interventions for, 314-317
 postdischarge, 327-344
 breastfeeding, 338
 fetal programming and, 328-329
 formulas, 334-336
 growth rate and, 329-333
 in bronchopulmonary dysplasia, 339-340
 in cardiac disease, 340
 minerals, 337
 protein, 337
 pain in. *See* Pain, in vulnerable neonates.
 very low birthweight. *See* Extremely low birthweight infants; Very low birthweight infants.
- Probiotics
 as immunonutrients, 57-58
 for short-bowel syndrome, 189
- Procaine penicillin G, for syphilis, 800
- Progressive familial intrahepatic cholestasis, 171-172
- Prokinetic agents
 for gastroesophageal reflux, 151-152
 pharmacology of, 117-126
- Prolactin, as pain marker, 422
- Proline, in nutrition, 73
- Prostaglandins, in hypoxic-ischemic brain injury, 592-593
- Protein. *See also* Amino acids.
 in formulas, for preterm infants, 337
 metabolism of, corticosteroids effects on, 305-306
 requirements of
 for fetal growth, 228-230
 for very low birthweight infants, 240
 in infections, 297-299, 301
 serum, monitoring of, in nutritional assessment, of preterm infants, 323
 supplements for, for preterm infants, 314-315, 317
 synthesis of, defects of, in hypoxic-ischemic brain injury, 637
- Protein C, activated, resistance to, fetal and newborn stroke in, 697
- Proton pump inhibitors
 for gastroesophageal reflux, 152
 pharmacology of, 126-127

- Pseudomonas aeruginosa*, in meningitis, 799
 Pyloric stenosis, surgical treatment of, 6-7
 Pyrimethamine, for toxoplasmosis, 816-817
 Pyruvate carboxylase deficiency, hypoglycemia in, 252

R

- Ranitidine, pharmacology of, 124-126
 Rationalization, in neonatal care workers, pain management decisions and, 563-565
 Reactive oxygen species, in hypoxic-ischemic brain injury, 589-590, 594
 Reflex
 diving, necrotizing enterocolitis pathophysiology and, 32-33
 laryngeal, for reflux protection, 140
 Reflux, gastroesophageal. *See* Gastroesophageal reflux.
 Regurgitation, in gastroesophageal reflux, 144
 Renin, as pain marker, 421
 Respiration
 heart rate variability with, 429-430, 435
 in endotracheal intubation, premedication effects on, 542
 Respiratory acidosis, bilirubin neurotoxicity in, 766, 770
 Respiratory depression, opioid-induced, 501
 Respiratory disorders, in very low birthweight infants, brain injury in, 781
 Respiratory sinus arrhythmia, 429
 Resuscitation
 in hypoxic-ischemic brain injury, 626-627, 629-632, 673-676
 stroke in, 706
 Ret gene, in enteric nervous system development, 107-108
 Riley Infant Pain Scale, 472, 476
 Rubella, of central nervous system, 812
 Rumination, in gastroesophageal reflux, 144
- S**
- Sacrococcygeal teratoma, fetal surgery for, 4-5
 Scale for Use in Newborns, for pain assessment, clinical utility of, 462
 Scintigraphy, in gastroesophageal reflux, 149
 Sclerosing cholangitis, 167
 Sedation, opioid-induced, 501-502
 Seizures
 in hypoglycemia, 661
 in hypoxic-ischemic brain injury, treatment of, 679-680
 in stroke, 707-708, 714
 opioid-induced, 502
 Sensitivity tests, in animal models of pain, 399-400
 Sensitization, to pain, in vulnerable neonates, 375, 377
 Sepsis
 bilirubin neurotoxicity in, 767
 catheter-related, in short-bowel syndrome, 188
 cholestasis in, 169-170
 metabolic effects of, nutritional aspects of, 296-302
 Short-bowel syndrome, 181-194
 complications of, 186-187
 definition of, 181
 etiology of, 182
 intestinal adaptation to, 182-183
 management of, 183-186
 enteral feedings in, 183-184
 medications in, 188-189
 parenteral nutrition in, 184-187, 191
 postoperative, 183
 surgical, 189
 transplantation in, 189-191
 pathophysiology of, 182
 Signaling pathways, in enteric nervous system development, 105-108
 Silo, spring-loaded, for gastroschisis, 12
 Sleep
 pain perception in, heart rate in, 433
 patterns of, in pain assessment, 471-473
 Small-for-gestational-age infants
 growth of, 329, 338-339
 hypoglycemia in, 248-249
 nutrition for, 339
 Small intestine
 adaptation of, in short-bowel syndrome, 182-183
 bacterial overgrowth in, in short-bowel syndrome, 187-188
 herniation of, through abdominal wall (gastroschisis), 11-12
 malrotation of, surgical treatment of, 9
 necrosis of, surgical treatment of, 12-13
 perforation of, spontaneous, 13

- resection of, short-bowel syndrome after.
See Short-bowel syndrome.
- transplantation of
 - for gastrointestinal anomalies, 16
 - for short-bowel syndrome, 189-191
- Social behavior, in pain assessment, 482
- Social conditions, postdischarge, for very low birthweight infants, 787
- Social context, of neonatal pain, 553-570
 - changing practices of, 556-558
 - communication aspect of, 553, 555-556
 - learning about pain, 565
 - pressure for change, 559-561
 - prevalence of pain, 554-555
 - research on, 567-568
 - resistance to change, 563-565
 - standards of care and, 565-567
- Sociocommunication model of pain, 446-454, 555-556
- Sodium, in amino acid transport, 210-211
- Sodium bicarbonate, as pain marker, 676
- Somatostatin, for short-bowel syndrome, 186
- Somatostatin analogues, for persistent hyperinsulinemic hypoglycemia of infancy, 250
- Sox10 transcription factor, of enteric nervous system development, 109
- Spiramycin, for toxoplasmosis, 817
- Spring-loaded silo, for gastroschisis, 12
- Standards of care, for pain management, 565-567
- Staphylococcus aureus*, in meningitis, 799
- Steroids. See Corticosteroids.
- Streptococci, group G, in meningitis, 797-798
- Stress, response to, 416-419
 - biological markers of, 418-422
 - in anesthesia, 419-420, 561-562
 - in animal models of pain, 401, 408
 - in fetus, 383, 512-513
 - in surgery, 419-420
 - with inadequate anesthesia, 561-562
- Stroke, 691-722
 - causes of
 - fetal factors, 700-704
 - maternal factors, 695-699
 - neonatal conditions, 705-707
 - peripartum, 704-705
 - placental disorders, 699-700
 - clinical features of, 707-708
 - epidemiology of, 691-693
 - evaluation of, 708-713
 - hemispheric involvement in, 710-711
 - history in, 692-693
 - imaging in, 708-711, 844
 - in intraventricular hemorrhage, neuroimaging in, 831-832
 - neurodevelopmental outcome of, 713-715
 - neurophysiologic studies in, 708-709
 - risk factors for, 694
 - timing of, from fetal to neonatal life, 693, 695
 - treatment of, 715-716
- Subepithelial cells, intestinal, in host defense, 48
- Succinylcholine, for premedication, for endotracheal intubation, 536, 541-542, 544, 547, 549
- Sudden infant death syndrome, gastroesophageal reflux and, 145
- Sufentanil, surgical stress response suppression due to, 417
- Sulfadiazine, for toxoplasmosis, 816-817
- Sulfonylurea receptor defects, in persistent hyperinsulinemic hypoglycemia of infancy, 249-250
- Surgery
 - metabolic response to, 296-297
 - postoperative pain in. See Postoperative pain.
 - stress response to
 - anesthesia effects on, 417-418
 - markers of, 418-422
 - without anesthesia, 559-560
- Suxamethonium, for premedication, for endotracheal intubation, 543, 549
- Syncytiotrophoblasts, nutrient transfer in, 205-206, 211-212
- Syphilis, of central nervous system, 800-801, 804-805
- Systemic lupus erythematosus, maternal, fetal and newborn stroke in, 695

T

- T lymphocytes, intraepithelial, in host defense, 45-46
- Temperament, neurodevelopmental outcome and, 382-383

- Temperature, in hypoxic-ischemic brain injury.
See Hypoxic-ischemic brain injury, temperature effects on; Hypothermia, for hypoxic-ischemic brain injury.
- Teratoma, sacrococcygeal, fetal surgery for, 4-5
- Thiopental
for hypoxic-ischemic brain injury, 681-682
for premedication, for endotracheal intubation, 538, 544, 546-547
- Thiopentone, for premedication, for endotracheal intubation, 539, 544
- Threonine, in nutrition, 73-74
- Thrifty hypothesis, in intrauterine growth, 203-205, 328-329
- Thrombophilia, maternal, fetal and newborn stroke in, 696-698
- Thrombosis, of placenta, fetal and newborn stroke in, 697-698
- Thromboxanes, in hypoxic-ischemic brain injury, 592-593
- Thyroid hormone
deficiency of, in very low birthweight infants, brain injury in, 781-782
gastrointestinal trophic effects of, 83-84
- Thyrotropin-releasing hormone, maternal, neurodevelopmental effects of, 735-736
- Tight junctions, of intestinal epithelium, in host defense, 46
- Tissue injury, in vulnerable neonates, animal models of, 398
- Tissue recombination studies, of enteric nervous system development, 102-103
- Tocolytics, neurodevelopmental effects of, 731-733
- Toddler Pre-schooler Postoperative Pain Scale, 473, 476
- Tolerance, of opioids, 503-504, 518
- Toxoplasmosis, of central nervous system, 815-817
- Trachea
intubation of, premedication for, 535-552
occlusion of, in fetus, for diaphragmatic hernia, 3-4
- Tracheoesophageal atresia, surgical treatment of, 8-9
- Transcriptional regulation, of enteric nervous system development, 108-109
- Transforming growth factor- α
gastrointestinal trophic effects of, 80-81
in host defense, 51
- Transforming growth factor- β , gastrointestinal trophic effects of, 84-85
- Transgenic models, for enteric nervous system, 104-105
- Transplantation
liver, for gastrointestinal anomalies, 15-16
small intestinal
for gastrointestinal anomalies, 16
for short-bowel syndrome, 189-191
- Treponema pallidum* infections, of central nervous system, 800-801, 804-805
- Triangular cord sign, in biliary atresia, 166
- Trk receptors, in enteric nervous system development, 108
- Trophic feeding, intestinal mucosal effects of, 67-68
- Tuberculosis, of central nervous system, 815
- Tumor necrosis factor- α
in hypoxic-ischemic brain injury, 591-592
in periventricular leukomalacia, 753
inhibitors of, for infections, 302
intestinal, in host defense, 50-51
- Twin-twin transfusion
stroke in, 701-702
treatment of, 5
- Twins, pain perception in, 513
-
- ## U
- Ultrasonography
in biliary atresia, 166
in gastrointestinal anomalies, 2-5
in intraventricular hemorrhage, 831-832
in periventricular leukomalacia, 832
in stroke, 710
- University of Wisconsin Children's Hospital Pain Scale, 484
- Ureaplasma urealyticum*, in central nervous system infections, 802-804
- Urinary retention, opioid-induced, 502
-
- ## V
- Vagal Tone Index, 430, 433

- Varicella-zoster virus, in central nervous system infections, 812
- Vascular access, for gastrointestinal disorders, 10
- Vascular endothelial growth factor, gastrointestinal trophic effects of, 82
- Vascular resistance, basal, of intestinal circulation, 24-29
in fetus, 24-25
in first postnatal month, 25-26
mechanisms of, 26-29
- Venous thrombosis, cerebral, stroke in, 707
- Ventilation, in hypoxic-ischemic brain injury, 678-679
- Ventriculoperitoneal shunt, in fetus, 5
- Very low birthweight infants
brain injury in, 777-795
pathogenesis of, 777-780
postdischarge social and environmental influences on, 787
predisposition to
clinical factors in, 780-784
environmental factors in, 784-787
definition of, 329
long-term growth of, 332
nutrition for, 225-244
aggressive, 227, 230-241
enteral, 237-241
general considerations in, 226-227
in early neonatal period, 238-240
in growing period, 240-241
inadequate, consequences of, 226-227
parenteral, 230-237
requirements for, 228-230
- Vidarabine, for herpes simplex virus infections, 807
- Viral infections
cholestasis in, 170
of central nervous system, 806-813
- Visual Analogue Scale, for pain assessment, 463-464, 471, 478
- Visual function, dietary fatty acids and, 268-270
- Vitamin(s)
deficiencies of
in infections, 300-302
in short-bowel syndrome, 187
for cholestasis, 175
in formulas, for preterm infants, 337
- Vitamin K
for periventricular-intraventricular hemorrhage, 747
maternal, neurodevelopmental effects of, 736
- Volvulus, surgical treatment of, 9
- Vomiting, in gastroesophageal reflux, 144
- von Gierke's disease, hypoglycemia in, 251
- Vulnerable neonates, pain in. *See* Pain, in vulnerable neonates.
-
- W**
- Weight
birth
adult and childhood nutritional abnormalities related to, 203-205, 213-214
regaining of, in premature infants, 318
very low. *See* Extremely low birthweight infants; Very low birthweight infants.
fetal, versus nutritional requirements, 228-230
gain of, in nutritional assessment, of preterm infants, 321-322
- White matter, injury of
in periventricular hemorrhage, 746
in periventricular leukomalacia, 750-755
- Withdrawal, from opioids, 503-504
-
- X**
- Xanthine oxidase inhibitors, for hypoxic-ischemic brain injury, 682-683
-
- Z**
- Zinc, in formulas, for preterm infants, 337

